

**R**osemary Audu is a Professor of Medical Virology at Lead City University and a Director of Research at the Nigerian Institute of Medical Research (NIMR). She is currently the head of Microbiology Department in the institute and she is an Emory Nigeria Research Training Program Director. She has a strong passion and commitment to standards hence, she led the two national reference laboratories in NIMR (Center for Human Virology and Genomics, and Center for Tuberculosis Research) to obtain international accreditation to ISO 1589:2012; making them the first public health laboratories in the country to attain such feat. Furthermore, she prepared the Center for Human Virology and Genomics to be listed as a WHO prequalification laboratory for in-vitro diagnostics making it the only center in West Africa.



Over the last two decades, she has worked in the field of HIV/AIDS and has evaluated various diagnostic tools for HIV screening, viral load testing, and has contributed immensely towards the development of the national algorithm for the early infant diagnosis of HIV using dry blood spots. She set up the first viral load testing facilities for HIV, HCV, and HBV in the country, as well as the first genotyping facilities for HIV, HCV and HPV. Rosemary Audu is a trained ASLM and ISO 15189 assessor.

She currently lectures and supervises postgraduate students at the Lead City University. She has also anchored several training programs for health workers on antiretroviral therapy and she supervised the development of the NIMR training manuals for doctors, pharmacists, nurses and laboratory scientists. She is currently the Training Coordinator at NIMR. Until recently, she was a member of the National ART Task team. She is a current member of the National Technical Working Group on Viral Hepatitis and a member of the World Health Organization, Africa Medical Devices Forum for COVID19 Technical Working Group. She is a past Fogarty fellow and a Heymann fellow of IANPHI leadership academy.

Rosemary Audu is coordinating her institutional response to the COVID pandemic and she is a member of the laboratory and research pillars of the Lagos State response to COVID-19. She also leads the Virus Natural History, Transmission and Diagnostic Technical Working Group of the Nigeria COVID-19 Research Consortium. She and her team are tracking and monitoring the disease in her country by continuous sequencing of SARS-CoV-2 virus. They are involved in the development of assays for detection of COVID-19 and other viruses causing Viral Haemorrhagic Fever. She is the program director for the NIMR Viral Haemorrhagic Fever Extramural Research Program.

## **CURRICULUM VITAE**

### **I. BIODATA**

Name: **Audu Rosemary Ajuma (Nee Okolo)**

Date of Birth: 30<sup>th</sup> September 1968

Division: Center for Human Virology and Genomics

Department: Microbiology

State of Origin: Kogi

LGA: Olamaboro

Marital Status: Married

No of Children: 3 (30yrs, 28yrs, 21yrs)

### **II. ACADEMIC APPOINTMENTS**

First Academic Appointment: Junior Research Fellow (NIMR) – 11<sup>th</sup> January 1993

Present Post: Director Research (NIMR) – 2018 to Date

Present Post: Professor of Medical Virology (Lead City University, Ibadan) – 2019 to Date

### **III. UNIVERSITY EDUCATION**

1. University of Lagos, Lagos 1996-2000
2. University of Lagos, Lagos 1991-1992
3. Ahmadu Bello University, Zaria 1986-1989

### **IV. ACADEMIC QUALIFICATION**

1. B.Sc. (Hons) Microbiology - 1989 ABU, Zaria
2. M.Sc. Medical Microbiology (Virology Specialty) - 1992 University of Lagos
3. Ph.D. Medical Microbiology (Virology Specialty) - 2000 University of Lagos

## **V. SCHOLARSHIPS AND FELLOWSHIPS**

1. Forgatty Fellowship in HIV/AIDS and Computer Applications at the National Institutes of Health, Bethesda, Maryland, USA. 2003
2. Heymann Fellow of International Association of National Public Health Institutes (IANPHI) Leadership Academy 2015
3. CDC and ATSDR Honor Award, The 2014 International Excellence in Partnering Award 2015

## **VI. HONOURS DISTINCTIONS AND MEMBERSHIP OF LEARNED SOCIETIES**

### **a. Distinguished contributions to national development**

Blazed the trail in the implementation of quality management system by leading the Center for Human Virology and Genomics, NIMR to achieve the following feat:

1. First clinical laboratory in Nigeria with ISO 9001:2008 certification - 2008
2. First public clinical laboratory in Nigeria with ISO 15189:2012 accreditation -2017
3. First clinical laboratory in West Africa to be listed as WHO prequalification Laboratory - 2018

### **b. Membership of learned societies**

1. American Society of Microbiology
2. African Society of Laboratory Medicine

### **c. Membership of editorial board and or journal reviews**

- Saudi Medical Journal (Reviewer) 2005 – 2010
- Editorial Board of Nigerian Journal of Clinical and Biomedical Research (Member) 2006 – To Date
- African Health Sciences (Reviewer) 2007
- African Medical Journal (Reviewer) 2009
- World Journal of Pediatrics (Reviewer) 2014
- African Journal of Reproductive Health (Reviewer) 2012 – To Date
- African Journal of Laboratory Medicine (Reviewer) 2012 – To Date

- Journal of Infectious Diseases (Reviewer) 2021
- AIDS Research and Human Retroviruses (Reviewer) 2021
- Global Health Action (Reviewer) 2020 - To Date
- International Journal of Microbiology (Reviewer) 2019 – To Date
- American Journal of Tropical Medicine and Hygiene (Reviewer) 2019 – To Date
- Clinical Medicine Journal (Reviewer) 2019 – To Date

## **VII. DETAILS OF SUPERVISION/WORK/RESEARCH EXPERIENCE**

### **a. Students Supervised and Qualifications**

#### **University of Lagos**

1. Femi Adebayo	MSc. Virology	2003 (Completed)
2. Mohammed Balogun	MSc. Biochemistry	2003 (Completed)
3. Emily Meshack	MSc. Medical Microbiology (Virology)	2004 (Completed)
4. Azuka Okwuraiwe	PhD Biochemistry	2009(Completed)
5. Samuel Amoo	MSc. Cell Biology	2011(Completed)
6. Mabel Uwandu	MSc. Biochemistry	2012 (Completed)
7. Olumuyiwa Salu	PhD Medical Micro (Virology)	2012 (Completed)
8. Chika Onwuamah	PhD Cell Biology	2012 (Completed)
9. Fehintola Ige	PhD Cell Biology	2015 (On-going)
10. Joseph Shaibu	PhD Virology	2017 (On-going)

#### **Lead City University**

1. Animasaun Olawale	MPhil/PhD Virology	2020 (On-going)
2. Akomolafe Busayo	MPhil/PhD Virology	2020 (On-going)
3. Akindele Ibukun	MPhil/PhD Virology	2020 (On-going)
4. Olufisayo Famuyiwa	MPhil/PhD Virology	2019 (On-going)

5.	Adekunle Adeluwoye	MPhil/PhD Virology	2019 (On-going)
6.	Temitope Ogunleye	MPhil/PhD Virology	2019 (On-going)

**b. Trainer and postgraduate examiner**

- Post Graduate Students at the Department of Medical Microbiology, College of Medicine, University of Lagos (Examiner) 2003 – To Date
- Global Fund Training for Laboratory Scientists (Trainer) 2004 – 2010
- Effective Project Planning and Evaluation in Health Research (Trainer)
  - 2007 – To Date
- Quality Management Training for Clinical Laboratory (Trainer)
  - 2009 – To Date
- Strengthening Laboratory Management Towards Accreditation (Trainer)
  - 2012 – To Date
- NIMR Pre-conference and young and early scientists for a (Trainer)
  - 2013 – To Date
- Career Development Course for African Society for Laboratory Medicine Conference (Trainer) 2014

**d. Consultancy services**

- Development of Guidelines for the Use of Antiretroviral (ARV) Drugs in Nigeria – Federal Ministry of Health 2005
- Paediatric HIV and AIDS Technical Working Group – Federal Ministry of Health
  - 2006 – 2010
- Laboratory Quality Assurance Technical Working Group (CDC)
  - 2006 - To Date
- Technical Advisory Committee for Laboratory and Blood Safety Component of National AIDS/STIs Control Programme (NASCP) 2006 – 2010
- National Task Team on Anti-Retroviral Therapy (Member) 2010 – 2016
- National Laboratory Quality Assurance Team (Member) 2010 – 2014
- Steering Committee on Trainings under the Consolidated GFATM Round 5, 8 & 9 Grants (Member) 2011
- Quality Auditor for the African Society for Laboratory Medicine SLIPTA 2014 – To Date

- National Technical Working Group on Viral Hepatitis (Member)
  - 2016 – To Date
- National HIV Drug Resistance Surveillance Technical Working Group (Member)
  - 2019 – To Date
- World Health Organization, Africa Medical Devices Forum
  - Technical Committee (Member) 2020

**e. Work Experience**

1. 1989-1990 - National Youth Service Corps at University of Lagos (Research Assistant)
2. 1993-1996 - Nigerian Institute of Medical Research (Junior Research Fellow)
3. 1997- 2000 - Nigerian Institute of Medical Research (Research Fellow II)
4. 2001- 2003 - Nigerian Institute of Medical Research (Research Fellow I)
5. 2004- 2007 - Nigerian Institute of Medical Research (Senior Research Fellow)
6. 2008-2013 - Nigerian Institute of Medical Research (Chief Research Fellow)
7. 2013 – 2018 Nigerian Institute of Medical Research (Deputy Director, Research)
8. 2018 - To Date Nigerian Institute of Medical Research (Director, Research)
9. 2019 – To Date Lead City University (Professor of Medical Virology)

**f. Head of academic department or units**

- 1996-2001 - Head, Diarrhoea Unit, Microbiology Dept., NIMR
- 2001- 2017 - Head, Human Virology Laboratory, NIMR
- 2017 – To Date - Head, Microbiology Department, NIMR

**g. Committees served on in NIMR**

- Scientific Seminar Committee (member) 2000 – 2013
- Housing Committee (member) 2004 – 2008
- Grant Writing Committee (member) 2010 – 2016
- Senior Management Committee (member) 2011 – To Date
- Scientific Conference Committee (Chair for 2yrs) 2012 – 2016

- Institutional Review Board 2012 – 2020
- Scientific Committee 2016 – To Date
- Training Committee (Chair) 2016 -To Date

**h. Community service**

- Children Bible Club in the community - 1994 – To Date
- Outreaches to children in hospitals and remand homes- 2010 – To Date
- Medical Evangelism to rural communities - 2014 – To Date

**i. Research Experience**

1. Potency, Efficacy and Seroepidemiology of Polioviruses and Measles Vaccines in Lagos Nigeria
2. Investigation of Rabies Virus in the Saliva of Apparently Healthy Dogs
3. The Aetiological Agents of Childhood Diarrhoea
4. Evaluation of Immunization Coverage in Pedro Village of Lagos State
5. Characterization of Rotavirus, Adenovirus, Astrovirus and other Viral Agents of Diarrhoea
6. Evaluation of HIV, HBsAg and HCV Test Kits
7. Defining CD4 Reference Values in Both Children and Adults in Nigeria
8. HIV/AIDS Drug Resistance Testing surveillance
9. Evaluation of Early Infant Diagnosis of HIV Using Dry Blood Spots
10. Hepatitis B Viral Load Estimation
11. Estimation of Hepatitis C Viral Load and Genotyping
12. Evaluation of National HIV Testing Algorithm
13. Isolation and characterization of Viral Haemorrhagic Fever
14. Surveillance of viral agents causing outbreaks
15. Clinical Characteristics of COVID-19 and Its Diagnostics

## **VIII. RESEARCH GRANTS**

### **a) Completed**

#### **1. Grant Source:** Genedrive Diagnostics Ltd.

**Project:** Performance evaluation of the Genedrive HCV ID Kit for decentralized diagnosis of active hepatitis C from human plasma

**Details:** Assessment of the analytical and clinical performance of the Genedrive® HCV ID Kit for the qualitative detection of HCV RNA in human whole-blood derived plasma in antibody positive, treatment naïve patients. Results from this study will be submitted as evidence to the WHO for Pre-Qualification of the Kit.

**Period:** 2019-2020

**Status:** On-going

**Role:** Principal Investigator

#### **2. Grant Source:** Foundation for Innovative and New Diagnostics

**Project:** Evaluation study of Rapid Diagnostic Tests (RDTs) detecting antibodies against hepatitis C virus

**Details:** The evaluation of RDT performance on clinical samples collected in different geographic regions as well as from HIV co-infected individuals, would allow to identify tests with a performance meeting or having the potential to meet WHO quality standards.

**Period:** 2018-2019

**Status:** Completed

**Role:** Principal Investigator

#### **3. Grant Source:** National Institutes of Health

**Project:** Multidisciplinary NeuroAIDS Research Training to Improve HIV Outcomes in Nigeria

**Details:** Risk screening and targeted detection of acute HIV infection in individuals with unsafe sex by applying a rapid assessment-based risk score algorithm, followed by HIV antibody rapid testing and nucleic acid amplification testing of participants.

**Period:** 2015-2016

**Status:** Completed

**Role:** Sub-recipient Principal Investigator

#### **4. Grant Source:** Institute of International Education

**Project:** Evaluation of the Compliance of Health Research Ethics Committees in Nigeria with Guidelines and International Ethical Standards

**Details:** To evaluate the operations of health research ethics committees in Nigeria in compliance with national and international standards

**Period:** 2015 - 2016

**Status:** Completed

**Role:** Principal Investigator

- 5. Grant Source:** University of Cambridge, Diagnostics Development Unit  
**Project:** In-country validation of SAMBA Point-of –Care Qualitative and Semi-Quantitative assays for early infant diagnosis and viral load monitoring of HIV-1 infection in Nigeria – Phase 1  
**Details:** To assess the performance, feasibility and operational efficacy of the SAMBA-Q and SAMBA–SQ assays at NIMR and JUTH laboratories in Nigeria.  
**Period:** 2014-2016  
**Status:** Completed  
**Role:** Site Investigator
- 6. Grant Source:** United States Center for Disease Control and Prevention (CDC)  
**Project:** HIV Drug Resistance: Implications for Optimizing Antiretroviral Therapy  
**Details:** To evaluate the DRMs among patients failing 1L ART, examine the patterns of adherence associated with the development of DRMs and assess the association between DRMs and subsequent response to 2L ART  
**Period:** 2013 - 2016  
**Status:** Completed  
**Role:** Co-Investigator
- 7. Grant Source:** Society for Family Health (SFH)  
**Project:** Global Fund HIV Round 9 Consolidated Grant on External Quality Assurance Programme for HIV Counselling and testing  
**Details:** To conduct an External Quality Assurance to further reassure the quality of testing and provide early warning for systematic problems associated with test kits or service operations at the service delivery points in Nigeria.  
**Period:** 2012-2016  
**Status:** Completed  
**Role:** Principal Investigator
- 8. Grant Source:** International Association of National Public Health Institute (IANPHI)  
**Project:** Establishing an External Quality Assessment Programme in Nigeria  
**Details:** To Establish External Quality Assessment Programme for HIV, TB and Malaria in Public and Private Laboratories in Nigeria  
**Period:** 2009-2011  
**Status:** Completed  
**Role:** Principal Investigator

**In progress**

- 1. Grant Source:** Nigerian Institute of Medical Research  
**Project:** Burden of Lassa Fever, Status of Its Management and Prevention in Nigeria  
**Details:** To provide information on the burden and molecular characteristics of Lassa fever virus (LASV) and other agents of Viral Haemorrhagic Fevers responsible for unconfirmed LASV cases in Ondo state.  
**Period:** 2018 – To Date  
**Status:** On-going  
**Role:** Principal Investigator

**2. Grant Source:** Nigerian Institute of Medical Research

**Project:** Viral Haemorrhagic Fevers and Their Reservoirs in Nigeria

**Details:** To characterize major viruses associated with VHF, provide information on main reservoirs of infection in VHF-prone areas and train a crop of young scientists in support of the National Control Program.

**Period:** 2019

**Status:** On-going

**Role:** Principal Investigator

**3. Grant Source: NIH Fogarty International Center D43**

**Project:** Emory-Nigeria HIV Research Training Program

**Details:** To support training for researchers interested in building a career in HIV/women's health research.

**Period:** 2019

**Status:** On-going

**Role:** Project Director (NIMR)

**4. Grant Source: African CDC/NCDC/UCL/NIMR**

**Project:** Population-based Seroepidemiological and Household Contact Study of COVID-19 Virus Infection in Nigeria

**Details:** To measure the seroprevalence of antibodies to COVID-19 in the population of selected states in Nigeria by sex and age group.

**Period:** 2020

**Status:** On-going

**Role:** Principal Investigator

**C. Dissertation and Thesis**

1. Bacterial Quality of Frozen, Semi-Frozen and Smoked Seafish From Retail Outlets in Zaria, 1989.
2. Potency and Efficacy of Trivalent Oral Poliovirus Vaccines (OPV) in Nigeria: A Case Study of Some EPI Centres in Lagos State, 1992.
3. Isolation and Molecular Typing of Some Viral Agents of Diarrhoea in Children Under 5 Years in Lagos, Nigeria, 2000.

## **PUBLICATIONS**

### **a. Articles in peer reviewed journals**

1. Esumeh FI, Audu RA, Odugbemi TO, et. al. (1991): Faecal Contamination Level, Survival of Salmonella Typhi and PH Changes in "Garri" and its Potential Public Health Hazard in Lagos. Niger. Med. J. 21(344): 86-89.
2. Ogbadu LI and Okolo RA. (1993): Bacteriological Quality of Frozen, Semi-Frozen and Smoked Seafish From Retail Outlets in Zaria. Bioscience Research Communications 5(1): 65-69.
3. AUDU RA, Omilabu A, Grange A, Abdulsalam N and Salami MYI. (1996): Seroepidemiology of Polioviruses and Efficacy of Oral Poliovirus Immunization in Lagos Nigeria. Nig. Quart. J. Hosp. Med. 6(4): 275-278.
4. Afolabi BM, Mafe AG, Audu RA, et al. (1997): Coastal Malaria and Nutritional Status of Children 0 - 6 Years Old in Lagos, Nigeria. The Nig. J. Med. Res. 1 (2): 28 - 31.
5. Afolabi BM, Sodeinde O and Audu RA. (1997): Malaria in Early Infancy on the Atlantic Coast of Lagos, Nigeria. The Nig. J. Med. Res. 1(2):32 - 36.
6. Adeiga A, Audu RA. (1996): Detection of Rabies Virus in the Saliva of Apparently Healthy Dogs in Lagos, Nigeria. Biomedical Letters. 54: 207-212.
7. Alabi SA, Audu RA, Oyedele KS, Mafe AG and Uhuangho JE. (1998): Viral, Bacterial and Parasitic Agents Associated With Infantile Diarrhoea in Lagos, Nigeria. The Nig. J. Med. Res. 2(1 & 2): 29 - 32.
8. Omilabu SA, Oyefolu AO, Audu RA, Ojo OO and Badaru SO. (1998): Potency Studies of Live-Attenuated Viral Vaccines Administered in Lagos Metropolis, Nigeria J. Nig. Infect. Control Assoc. 1(1): 27 - 33.
9. Oyefolu AO, Omilabu SA, Amure OF, Adeniyi AS, Audu RA, Fadojutimi JA, Akinyemi KO and Ashiru O. (1998): Potency Status of Trivalent Oral Polio Vaccines (TOPV) Administered in Lagos, Nigeria. Nig. Quart. J. Hosp.Med. 8(1): 14 - 17.
10. Adeiga AA, Akinoshio RO, Audu RA and Onywuchie J. (1999): Estimation of Measles Sero-Conversion in Children Vaccinated Against Measles in Edo State of Nigeria. Nig.Quart. J. Hosp.Med. 9(2): 169-171.
11. Omilabu SA, Oyefolu AO, Ojo OO and Audu RA. (1999): Potency Status and Efficacy of Measles Vaccine Administered in Nigeria: A Case Study of Three EPI Centres in Lagos, Nigeria. Afr. J. Med. Med. Sci. Sep-Dec; 28 (3-4): 209 – 212.
12. Audu RA, Omilabu SA, Renner JK and Awodiji JA. (2000): Risk Factors, Clinical Features and Management of Children with Diarrhoea in Lagos. J. Nig. Infect. Con. Assoc. 3(1): 24-29.
13. Idika N, Audu RA, Oyedele KS, Iyanda R and Egbom CA. (2000): Investigation of Different Water Sources as a Possible Cause of Cholera Outbreak in Lagos in 1997. J. Nig. Infect. Con. Assoc. 3 (2):6-8.
14. Adeiga, A, Akinoshio RO, Audu RA and Onywuchie. (2000): Status of Tetanus Antibodies in the Newborns of Immunized Mothers. J. Med & Medical Sci. July-Dec, Vol. 2(2): 125-128.
15. Audu RA, Omilabu SA and Onile BA (2001): The Prevalence of Rotavirus, Adenovirus and Astrovirus in Children with Diarrhoea in Ilorin Kwara State, Nigeria. Afr. J. Clin. Exp. Micro. 2(2): 20-22.
16. Audu R, Omilabu SA, De Beer M, Peenze I and Steele AD (2002): Diversity of

- Human Rotavirus VP6, VP7, and VP4 in Lagos State, Nigeria. *J. Health Popul. Nutr.* 20:59-64.
17. Afolabi BM, **Audu RA**, Olukosi A (2002): Nutritional Status of Preschool Children in Rural Coastal Nigeria. *Journal of Malaria in Africa & The Tropics.* 1(1):36-38.
  18. **Audu RA**, Omilabu SA, Peenze I and Steele D. (2002): Viral Diarrhoea in Young Children in Two Districts in Nigeria. *The Cent Afr J Med.* 48(5/6): 59-63.
  19. **Audu RA**, Omilabu Aremu S, Peenze Ina, Steele Duncan A. (2002): Isolation and Identification of Adenovirus Recovered From the Stool of Children With Diarrhoea in Lagos, Nigeria. *Afr.J.Health Sci.* 9: 105-111.
  20. Salu OB, **Audu RA**, Geyer A, Steele AD and Oyefolu AOB (2003): Molecular Epidemiology of Rotaviruses in Nigeria: Detection of Unusual Strains With G2P[6] and G8P[1] Specificities. *J. Clin. Micro.* 41(2): 913-914.
  21. Ebuehi, OAT, Balogun, MO, **Audu RA**, Idigbe, EO (2004): Osmotic Fragility and Na<sup>+</sup> - K<sup>+</sup> ATPase Activity of Erythrocytes of HIV/AIDS Patient. *Afr. J. Clin & Exp. Micro.* 5(2): 148-154.
  22. Ebuehi, OAT, Balogun, MO, **Audu RA**, Idigbe, EO (2004): Blood Chemistry and Platelet Serotonin Uptake As Alternative Method Tracking HIV/AIDS. *Afr. J. Clin & Exp. Micro.* 5(2): 155-159.
  23. **Audu RA**, Akanmu AS, Efienemokwu C, Musa AZ, Lemoha E, Odunaike MI, Funso-Adebayo EO, Meshack E and Idigbe EO (2004): Changes in Serum Proteins and Creatinine Levels in HIV Infected Nigerians. *Nigerian Journal of Health and Biomedical Sciences.* 3(2): 69-72.
  24. **Audu RA**, Akanmu AS, Efienemokwu C, Dele AZ, Lemoha E, Odunaike MI, Aniedobe M and Idigbe EO (2004): Impact of Tuberculosis Co-Infection on the Level of PCV in HIV Infected Patients. *Nig. Quart. Hosp. Med.* 14(2): 115- 117.
  25. Ebuehi, OAT, Balogun, MO, **Audu RA**, Idigbe, EO (2004): Osmotic Fragility and Na<sup>+</sup> - K<sup>+</sup> ATPase Activity of Erythrocytes of HIV/AIDS Patient. *Afr. J. Clin & Exp. Micro.* 5(2): 148-154.
  26. Adeiga A, Akinosh O, **Audu RA**, Onywuche J and Oyewole O (2004): Placental Transfer of Measles Antibodies in Nigerian Mothers. *Br. J. Biomed. Sci.* 61(1): 37-39.
  27. **Audu RA**, Onwujekwe DI, Onubogu CC, Adedoyin JA, Onyejepu N, Mafe AG, Onywuche J, Oparaugo C, Enwuru C, Aniedobe M, Musa AZ and Idigbe EO. (2005): Possible Impact of Co-Infections of Tuberculosis and Malaria on the CD4+ Cell Counts of HIV Patients in Nigeria. *Annals of African Medicine.* Vol 4(1): 10-13.
  28. Adeiga A, Omilabu SA, **Audu RA**, Sanni F, Lakehinde GP, Balogun O and Olagbaju O (2005): Tetanus Toxoid Immunization Coverage among Mothers of Children Below One Year of Age in Difficult-To-Reach Area of Lagos Metropolis. *Afr. J. Clin & Exp. Micro.* 6(2): 233-237.
  29. Adeiga A, Omilabu SA, **Audu RA**, Sanni F, Lakehinde GP, Balogun O and Olagbaju O (2005): Infant Immunization Coverage in Difficult-To-Reach Area of Lagos Metropolis. *Afr. J. Clin & Exp. Micro.* 6(2): 227-231.
  30. Idigbe EO, Adewole T, Kanki P, Eisien G, Odunukwe DI, **Audu RA**, Araoyinbo I, Salu OB, Adedoyin JA and Musa AZ (2005): Management of HIV-1 Infection with a Combination of Nevirapine, Stavudine, Lamivudine: A Preliminary Report on the Nigerian ARV Program. *J. Acquir. Immune Defic. Syndr.* 40(1):65-69.
  31. Ebuehi OAT, Balogun M, Ebuehi OM, **Audu RA** and Idigbe EO (2005): Urinary

- Creatinine Levels in HIV/AIDS Disease. European Journal of Scientific Research 10 (1): 60-65.
32. Odunukwe N, Idigbe O, Kanki P, Adewole T, Onwujekwe D, **Audu R** and Onyewuche J (2005): Haematological and Biochemical Response to Treatment of HIV-1 Infection with a Combination of Nevirapine + Stavudine + Lamivudine in Lagos Nigeria. Turk. J. Haematol. 22(3): 125-131.
  33. Idigbe EO, **Audu RA**, Salu OB, Onyewuche JI, Oparaugo CT, Musa AZ, Meshak EH and Sylvester-Ikondou UF (2006): Profile of Baseline CD4 T-Lymphocyte and Viral Load Levels in HIV Infected Treatment Naïve Patients in Lagos, Nigeria. Saudi Medical Journal 27 (5):733 -735.
  34. Idigbe EO, Odutolu O, Okonkwo P, Folayan MO, Uwakwe CBR, **Audu RA**, Jolayemi OM and Osagbemi M. (2006). Evaluation of The Nigerian National Antiretroviral (ARV) Treatment Training Programme. Sahara Journal, 3(3): 488-502.
  35. Idigbe EO, **Audu RA**, Oparaugo CT, Onwujekwe D, Onubogu CC, Adedoyin J, Mafe AG, Okoye R, Onyewuche JI, Funso-Adebayo EO and Meshack E. (2006). Comparison of Dynabeads and Capcellia Methods with Facscount for the Estimation of CD4 T Lymphocyte Levels in HIV/AIDS Patients in Lagos, Nigeria. East Afr. Med. J. 83(4): 105-111.
  36. **Audu RA**, Salu OB, Musa AZ, Onyewuche J, Funso-Adebayo EO, Iroha EO, Ezeaka VC, Adetifa IMO, Okoeguale B and Idigbe EO. (2006): Estimation of the Rate of Mother-To-Child Transmission of HIV in Nigeria. Afr. J. Med. Med. Sci. 35 (2): 121 – 124.
  37. Oyefolu AOB, Nwaeke AC, **Audu RA**, Akinyemi KO, Salu OB, Muller CP and Omilabu SA. (2007) Evaluation of Measles Vaccine Cold Chain in Lagos State, Nigeria. Afr. J. Clin & Exp. Micro. 8 (1): 1 - 7.
  38. **Audu RA**, Idigbe EO, Akanmu AS, Mafe AG, Onyewuche J, Oparaugo CT, Dele AZ, Salu OB, Lemoha E and Odunaike M. (2007). Values of CD4+ T Lymphocyte in Apparently Healthy Individuals in Lagos, Nigeria. European Journal of Scientific Research 16 (2): 168 - 173.
  39. Oladepo DK, Idigbe EO, **Audu RA**, Inyang US, Imade GE, Philip AO, Okafor GO, Olaleye D, Mohammed SB, Odunukwe NN, Harry TO, Edyong-Ekpa M, Idoko J, Musa AZ, Adedeji A, Nasidi A, Ya'aba Y and Ibrahim K. (2009): Establishment of Reference Values of CD4 and CD8 Lymphocyte Subsets in Healthy Nigerian Adults. Clinical and Vaccine Immunology, 16(9): 1374-1377.
  40. Idigbe EO, **Audu RA**, Iroha EO, Akinsulie AO, Temiye EO, Ezeaka VC, Adetifa IMO, Musa AZ, Onyewuche J and Ikondou SU (2010): T-Lymphocyte Subsets in Apparently Healthy Nigerian Children. International Journal of Pediatrics Vol 2010, Article ID 474380.
  41. Ezech Oliver C; Jogo Andrea; Gab-Okafor Chidinma; Onwujekwe Dan I; Ezeobi Paschal M; Gbajabiamila Titi; Adu Rosemary A; **Audu Rosemary A**; Musa Adesola Z; Salu Olumuyiwa B; Meschack Emily; Herbertson Ebere; Odunukwe Nkiru; Idigbe Oni E (2010): Effect of HIV-1 Infection and Increasing Immunosuppression on Menstrual Function. The J. of Obstetrics and Gynaecology Research ;36(5):1053-8.
  42. Afe AJ, Adewumi N, Emokpae A, Fagoralad T, Disub AE, Abidoyeb G, Ganikalee I and **Audu R**. (2011): Outcome of PMTCT Services and Factors Affecting Vertical Transmission of HIV Infection in Lagos, Nigeria. HIV & AIDS

- Review, 10 (1), P.14-18, Mar 2011  
doi:10.1016/j.hivar.2011.02.001.
43. Okwuraiwe AP, Salu OB, Onwuamah CK, Amoo OS, Odunukwe NN and **Audu RA**. (2011): Experience with Hepatitis B Viral Load Testing in Nigeria. *Afr. J. Clin & Exp. Micro. Afr. J. Clin & Exp. Micro.* 12 (3): 101 – 105.
44. Butali A, Mossey PA, Adeyemo WL, Jezewski P, Onwuamah CK, Omobolanle O, Ugboko VO, Adejuyigbe O, Adigun IA, Abdur-Rahman LO, Onah I, **Audu R**, Idigbe E, Mansilla MA, Ecaterina D, Petrin AL, Bullard SA, Uduezue A, Akpata O, Osaguona A, Olasoji OH, Ligali L, Kejeh B, Iseh K, Olaitan P, Adebola A, Efunkoya A, Adesina A, Oluwatosin O and Murray JC (2011): The Nigeria CRAN Collaboration. Genetic Studies in The Nigerian Population Implicate a msx1 Mutation in Complex Oral Facial Clefting Disorders. *Cleft Palate Craniofac J.* 48(6): 646–653. doi:10.1597/10-133.
45. Nwokoye NN, **Audu RA**, Onubogu CC, Raheem TY, Okoye R, Aniedobe M, Onwuamah CK, Nduaga S and Idigbe EO (2011). Panel Testing of AFB smear microscopy among laboratories in Nigeria. *Journal of Clinical and Biomedical Research.* Vol 5 No 1 Supplement 2, 50 – 54.
46. Onykwere CA, **Audu RA**, Duro-Emmanuel F and Ige FA (2012): Hepatitis D Infection in Nigeria. *Indian J Gastroenterol.* 31 (1):34-35. doi:10.1007/s1 2664-011-0158-9.
47. **Audu RA**, Sylvester-Ikondou U, Onwuamah CK, Salu OB, Ige FA, Meshack E, Aniedobe M, Amoo OS, Okwuraiwe AP, Okhiku F, Okoli CL, Fasela EO, Odewale EO, Aleshinloye RO, Olatunji M and Idigbe EO. (2012): Experience of Quality Management System in a Clinical Laboratory in Nigeria. *Afr J. Lab. Med.* 2012;1(1), art. #18, 5 Pages. <http://dx.doi.org/10.4102/AJLM.V1I1.18>.
48. Ezechi OC, Gab-Okafor CV, Oladele DA, Kalejaiye OO, Oke BO, Ekama SO, **Audu RA**, Okoye RN, Ujah IA. (2012): Prevalence and Risk Factors of Asymptomatic Bacteriuria among Pregnant Nigerians Infected with HIV. *J Matern Fetal Neonatal Med.* 2013 Mar;26(4):402-6. doi: 10.3109/14767058.2012.733782. Epub 2012 Nov 30.
49. Okwuraiwe AP, **Audu RA**, Salu OB, Onwuamah CK, Amoo OS, Ige FA, Mechack EH, Jamda PD, Odunukwe NN, Onwujekwe DI, Ezechi OC, Idigbe EO. Immunological and virological response to HAART in HIV-1 patients co-infected with Hepatitis B and C viruses. *West African Journal of Medicine.* 2012; **31**(2): 124-128.
50. Okwuraiwe AP, Salu OB, Anomneze E, **Audu RA**, and Ujah IAO. Hepatitis C Virus Genotypes and Viral Ribonucleic Acid Titers in Nigeria. *Nigerian Journal of Gastroenterology and Hepatology.* 2012; **4**(2): 67-71.
51. Amoo OS, Taiwo IA, Salu OO, Okwuraiwe AP, Onwuamah CK, Awe MA, Oforomeh OO, Onwujekwe DI, Ezechi OC and **Audu RA** (2013): Comparison of the COBAS/Ampliprep Taqman and Amplicor HIV-1 monitor tests in Lagos, Nigeria. *Afr J Lab Med.* 2013;2(1), Art.#68, 4 pages. <http://dx.doi.org/10.4102/ajlm.v2i1.68>.
52. Uwando MO, Okwuraiwe AP, Amoo OS, **Audu RA**, Okoye RN, Oparaugo CT, Onwuamah CK and Magbagbeola OA. (2013): Lipid Profile of Drug Naïve HIV Patients in a Tertiary Health Facility in Lagos, Nigeria. *Afr.J.Clin.Exper.Microbiol* 14(2):51-55 <http://dx.doi.org/10.4314/ajcem.v14i2.2>.
53. Olaleye OA, Kuti O, Makinde NO, Ujah IAO, Olaleye OA, Badejoko OO, Akintayo

- AA and **Audu R**. Perinatal transmission of hepatitis B virus infection in Ile-Ife, South Western, Nigeria. Journal of Neonatal-Perinatal Medicine, vol. 6, no. 3, 2013, pp. 231-236. DOI: 10.3233/NPM-1366412.
54. Rawizza HE, Chaplin B, Meloni ST, Darin KM, Olaitan O, Scarsi KK, Onwuamah CK, **Audu RA**, Chebu PR, Imade GE, Okonkwo P and Kanki PJ. Accumulation of protease mutations among patients failing second-line antiretroviral therapy and response to salvage therapy in Nigeria. PLoS ONE 2013 Sep 17;8(9): e73582. Doi:10.1371/journal.pone.0073582.
55. Onwuamah CK, Ekama SO, **Audu RA**, Ezechi OC, Poirier MC and Odeigah PGC. Exposure of Allium cepa Root Cells to Zidovudine or Nevirapine Induces Cytogenotoxic Changes. PLoS ONE 2014 Mar 5;9(3): e90296. doi:10.1371/journal.pone.0090296.
56. Ezechi OC, Kalejaiye OO, Gab-Okafor CV, Oladele DA, Oke BO, Musa ZA, Ekama SO, Ohwodo H, Agahowa E, Gbajabiamilla T, Ezeobi PM, Okwuraiwe A, **Audu RA**, Okoye RN, David AN, Odunukwe NN, Onwujekwe DI, Ujah IAO. Sero-prevalence and factors associated with Hepatitis B and C co-infection in pregnant Nigerian women living with HIV Infection. The Pan African Medical Journal. 2014;17:197.
57. **Audu RA**, Onubogu CC, Nwokoye NN, Ofuche E, Baboolal S, Oke O, Luman ET and Idigbe EO. Improving quality in national reference laboratories: The role of SLMTA and mentorship. Afr J Lab Med. 2014;3(2), Art. #200, 7 pages. <http://dx.doi.org/10.4102/ajlm.v3i2.200>.
58. Musa AZ, Yusuf BO, Gbajabiamila TA, Nwogbe OA, Ekama SO, **Audu RA**, Onwujekwe D, Ezechi OC, Idigbe EO, Ujah IOA (2014): Incidence And Risk Factors For First-Line Antiretroviral Therapy Failure Among Adult Nigerians. Nigerian Journal of Clinical & Biomedical Research Vol. 7 No. 3 25 – 35.
59. Onwuamah CK, Ezechi OC, Herbertson EC, **Audu RA**, Ujah IAO and Odeigah PGC. Foetal Loss and Enhanced Fertility Observed in Mice Treated with Zidovudine or Nevirapine. PLoS ONE 2014 Sep 18; 9(9): e107899. doi:10.1371/journal.pone.0107899. PloS one. 2014 Sep 18;9(9):e107899.
60. **Audu RA**, Onubogu CC, Okoye RN, Nwokoye NN, Onwuamah CK, Musa AZ, Raheem TY, Aniedobe MN, Nduaga SJ, Essien I and Idigbe EO. Proficiency testing for HIV, tuberculosis and malaria diagnosis in clinical laboratories in Nigeria. Afr J Lab Med. 2014;3(1), Art. #102, 9 pages. <http://dx.doi.org/10.4102/ajlm.v3i1.102>.
61. **Audu RA**, Onwuamah CK, Salu O, Okwuraiwe A, Ou CY, Bolu O, Bond K, Diallo K, Lu L, Jelpe T, Okoye M, Ngige E, Vertefeuille J. Development and Implementation Challenges of a Quality Assured HIV Infant Diagnosis Program in Nigeria Using Dried Blood Spots and DNA Polymerase Chain Reaction. AIDS Research and Human Retroviruses. 2014; 30(00): 6 pages. DOI: 10.1089/aid.2014.0159.
62. Musa AZ, Yusuf BO, Gbajabiamila TA, Nwogbe OA, Ekama SO, **Audu RA**, Onwujekwe D, Ezechi O.C, Idigbe EO, Ujah IOA. Incidence and Risk Factors for First-Line Antiretroviral Therapy Failure Among Adult Nigerians. Nigerian Journal of Clinical & Biomedical Research June 2014 Vol. 7 No. 3: 25 – 35.
63. Nwaokorie FO, **Audu RA**, Nwokoye NN, Okoye RN, Odunukwe NN, Idigbe EO, Ujah IAO. Improving Laboratory Quality Management System In Nigeria: The Nigerian Institute Of Medical Research Perspective. Nigerian Journal of Clinical

- & Biomedical Research, 2014; 7(4):29-40.
64. Butali A, Mossey P, Tiffin N, Adeyemo W, Eshete M, Mumena C, **Audu R**, Onwuamah C, Agbenorku P, Ogunlewe M, Adebola A, Olasoji H, Aregbesola B, Braimah R, Oladugba A, Onah I, Adebiyi E, Olaitan P, Abdur-Rahman L and Adeyemo A. Multidisciplinary approach to genomics research in Africa: the AfriCRAN model. Pan African Medical Journal. 2015; 21:229 doi:10.11604/pamj.2015.21.229.7380.
65. **Audu RA**, Okoye RN, Onwuamah CK, Ige FA, Musa AZ, Odunukwe NN, Onwujekwe DI, Ezechi OC, Emmanuel O, Idigbe EO and Kanki PJ. Potential for false-positive HIV test results using rapid HIV testing algorithms. Afr J Lab Med. 2015;4(1), Art. #178, 5 pages. <http://dx.doi.org/10.4102/ajlm.v4i1.178>.
66. Odunukwe NN., Okwuzu JO., Okwuraiwe AP., Gbajabiamila TA., Musa AZ., Ezeobi PM., Somefun EO, Kalejaiye OO, Onwujekwe DI, Salu OB, Onwuamah CK, **Audu RA** and Ezechi OC. Selenium as Adjunct to Highly Active Antiretroviral Therapy (HAART) in the Management of HIV/Hepatitis B Virus Co-Infection: A Randomized Open Label Study. African Journal of Clinical and Experimental Microbiology; 2016 July, 17(3): 197-204.
67. Olotu AA, Oyelese AO, Salawu L, **Audu RA**, Okwuraiwe AP, Aboderin AO. Occult Hepatitis B Virus Infection in Previously Screened, Blood Donors in Ile-Ife, Nigeria: Implications for Blood Transfusion and Stem Cell Transplantation. Virology Journal 2016; 13:76. DOI 10.1186/s12985-016-0533-3.
68. Ige FA, Nduaga SJ, Issa A, Kalejaiye OO, **Audu RA** and Ujah IAO. Blood Group, HIV and HBsAg Status of Apparently Healthy Nigerians. Nig. J. Clin & Biomed. Res. 2016; 7(3): 40-45.
69. Eshete MA, Liu H, Li M, Adeyemo WL, Gowans LJJ, Mossey PA, Busch T, Deressa W, Donkor P, Olaitan PB, Aregbesola BS, Braimah RO, Oseni GO, Oginni F, **Audu R**, Onwuamah C, et al. Loss-of-Function GRHL3 Variants Detected in African Patients with Isolated Cleft Palate. J Dent Res. 2017 Sep 1:22034517729819. doi: 10.1177/0022034517729819.
70. Meloni ST, Onwuamah CK, Agbaji O, Chaplin B, Olaleye DO, **Audu R**, Samuels J, Ezechi O, Imade G, Musa AZ, Odaibo G. Implication of First-Line Antiretroviral Therapy Choice on Second-Line Options. In Open forum infectious diseases 2017 Nov 2 (Vol. 4, No. 4, p. ofx233). US: Oxford University Press.
71. Chaplin B, Imade G, Onwuamah C, Odaibo G, **Audu R**, Okpokwu J, Olaleye D, Meloni S, Rawizza H, Muazu M, Musa AZ. Distinct Pattern of Thymidine Analogue Mutations with K65R in Patients Failing Tenofovir-Based Antiretroviral Therapy. AIDS research and human retroviruses. 2018 Feb 1;34(2):228-33.
72. Adetunji AA, Kuti MA, **Audu RA**, Muyibi SA, Imhansoloeva M, Mosuro OA, Solanke EA, Akpa OM, Irabor AE, Ladipo MM, Berzins B. Discordant rapid HIV tests: lessons from a low-resource community. HIV medicine. 2018 Jan 1; 19(1):72-6.
73. Gowans LJJ, Oseni G, Mossey PA, Adeyemo WL, Eshete MA, Busch TD, Donkor P, Obiri-Yeboah S, Plange-Rhule G, Oti AA, Owais A, Olaitan PB, Aregbesola BS, Oginni F, Bello S, **Audu R**, Onwuamah C, Agbenorku P, Ogunlewe MO, Abdur-Rahman LO, Marazita ML, Adeyemo AA, Murray JC, Butali A. *The Cleft Palate-Craniofacial Journal*. First Published February 28, 2018. <https://doi.org/10.1177/1055665618754948>
74. **Audu R**, Onwuamah C, Okpokwu J, Imade G, Odaibo G, Okwuraiwe A, Musa Z,

- Chebu P, Ezechi O, Agbaji O, Olaleye D, Samuel J, Dalhatu I, Ahmed M, DeVos J, Yang C, Raizes E, Chaplain B, Kanki P and Idigbe E. Genotyping performance evaluation of commercially available HIV-1 drug resistance test. *PloS one*. 2018 Jun 28;13(6): e0198246.
75. Lesi OA, **Audu RA**, Okwuraiwe AP, Adeleye OO, Ige FA, Iwuorah JC. Serological and virological markers of nigerian patients with hepatitis B infection. *Niger J Clin Pract* 2019; 22:534-8.
76. Amoo OS, Taiwo IA, Oliver E, Odewale E, Onwuamah CK and **Audu RA**. Adiposity and Reproductive Function in Nigerian Men Seeking Fertility Treatment in a Tertiary Healthcare Facility in Lagos, Nigeria. *Nigerian Hospital Practice* 2019; 24(1-3): 17-22.
77. Butali A, Mossey PA, Adeyemo WL, Eshete MA, Gowans LJ, Busch TD, Jain D, Yu W, Huan L, Laurie CA, Laurie CC.....**Audu R**..... Genomic analyses in African populations identify novel risk loci for cleft palate. *Human molecular genetics*. 2019 Mar 15;28(6):1038-51.
78. Onwuamah CK, Okpokwu J, **Audu R**, Imade G, Meloni ST, Okwuraiwe A, Chebu P, Musa AZ, Chaplin B, Dalhatu I, Agbaji O. Low levels of HIV-1 drug resistance mutations in patients who achieved viral re-suppression without regimen switch: a retrospective study. *BMC microbiology*. 2020 Dec 1;20(1):17.
79. Vetter BN, Reipold EI, Ongarello S, **Audu R**, Ige FA, Alkhazashvili M, Chitadze N, Vanroye F, De Wegheleire A, Sokkab A, Fransen K. Sensitivity and specificity of rapid diagnostic tests for hepatitis C virus with or without HIV coinfection: a multicentre laboratory evaluation study. *The Journal of Infectious Diseases*. 2020 Jul 2.
80. Olufemi Samuel Amoo, Aigbe Gregory Ohihoin, Adesola Zaidat Musa, Ifeoma Idigbe, Fehintola Ige, Temie Giwa-Tubosun, Sodiq Oloko, Aisha Abiola, Esther Ngozi Ohihoin, Agatha Ngozi David, Abideen Salako, David Oladele, Chidinma Muoghalu Gab-Okafor, Tajudeen Akanji Bamidele, Oluwagbemiga Olanrewaju Aina, Emelda Chukwu, Nkiruka Nnonyelum Odunukwe, Oliver Chukwujekwu Ezechi, **Rosemary Ajuma Audu**, Babatunde Lawal Salako. Implementation of a modified drive-through sampling strategy for SARS-CoV-2-the Nigerian experience. *Pan African Medical Journal*. 2020;35:(Supp 2):107. Published on 09 Jul 2020.
81. Emelda E Chukwu, David A Oladele, Oluwatoyin B Awoderu, Ebelechukwu E Afocha, Rahman G Lawal, Ismail Abdus-salam, Folasade T Ogunsola, **Rosemary A Audu**. A national survey of public awareness of antimicrobial resistance in Nigeria. *Antimicrobial Resistance & Infection Control* (2020/12) 9: 1-10.
82. Olumuyiwa Babalola Salu, Olufemi Samuel Amoo, Joseph Ojonugwa Shaibu, Chukwuyem Abejegah, Oluwafemi Ayodeji, Adesola Zaidat Musa, Ifeoma Idigbe, Oliver Chukwujekwu Ezechi, **Rosemary Ajuma Audu**, Babatunde Lawal Salako, Sunday Aremu Omilabu. Monitoring of lassa virus (LASV) infection in suspected and confirmed cases in Ondo State, Nigeria. *Pan African Medical Journal*. 2020 Aug 6;36(253).
83. Amoo OS, Aina OO, Okwuraiwe AP, Onwuamah CK, Shaibu JO, Ige F, Owaneze K, Agboola HO, Kareithi DN, Onuigbo TI, Ikemefuna AS, Oraegbu JI, Odewale EO, Okoli LC, Ajibaye O, James AB, Idris G, Ohihoin G, Tijani B, Giwa-Tunbosun T, Adegbola R, Salako BL, **Audu RA**. COVID-19 Spread Patterns Is

- Unrelated to Malaria Co-Infections in Lagos, Nigeria. *Advances in Infectious Diseases*. 2020 Oct 16;10(5):200-15.
84. Idigbe IE, Musa AZ, Amoo OS, Salu OB, Shaibu JO, Abejegah C, Ayodeji OO, Ezechi OC, Omilabu SA, **Audu RA** and Salako BL. 2020. Dealing with Lassa fever: Managing and curtailing the virus from the healthcare workers perspective in Nigeria. *Trends in Research*. Volume 3:1-2. doi: 10.15761/TR.1000159.
85. Idigbe IE, Salu OB, Amoo OS, Musa AZ, Shaibu JO, Abejegah C, Ayodeji OO, Ezechi OC, Omilabu SA, **Audu RA** and Salako BL. 2020. Dealing with stigma and its impact on Lassa-fever survivors in Ondo state. *Trends in Research*. Volume 3:1-2. doi:10.15761/TR.1000158
86. Chukwu EE, Oladele DA, Enwuru CA, Gogwan PL, Abuh D, **Audu RA**, Ogunsola FT. Antimicrobial resistance awareness and antibiotic prescribing behavior among healthcare workers in Nigeria: a national survey. *BMC Infectious Diseases*. 2021 Dec;21(1):1-2.
87. Shaibu JO, Onwuamah CK, James AB, Okwuraiwe AP, Amoo OS, et al. (2021) Full length genomic sanger sequencing and phylogenetic analysis of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) in Nigeria. *PLOS ONE* 16(1): e0243271. <https://doi.org/10.1371/journal.pone.0243271>
88. Uwandu, M.O., Ige, F.A., Okwuraiwe, A.P., Onwuamah, C.K., and **Audu, R.A.** (2021). Implementation of biosafety in infection control: a 10-year review. *African Journal of Clinical and Experimental Microbiology*. ISSN 1595-689X Apr 2021; Vol.22 No.2 AJCEM/2054. Accepted; Nov 2020.
89. **Rosemary Ajuma Audu**, Azuka Patrick Okwuraiwe, Fehintola Anthonia Ige, Olufunke Oluwatosin Adeleye, Charles Asabamaka Onyekwere, Olufunmilayo Adenike Lesi. Hepatitis C viral load and genotypes among Nigerian subjects with chronic infection and implication for patient management: a retrospective review of data. *Pan African Medical Journal*. 2020;37:335. Published on 10 Dec 2020
90. **Rosemary R. Audu**, Chika K. Onwuamah, Azuka P. Okwuraiwe, Olufemi S. Amoo, Ayorinde B. James, Joseph O. Shaibu, Fehintola A. Ige, Aigbe G. Ohihoi, Agatha N. David, Gideon O. Liboro, Ebenezer O. Odewale, Judith Sokei, Chika L. Okoli, Dominic A. Achanya, Adesegun A. Adesan, Bosede O. Amuda, Ponmak D. Jamda, Rahaman Ahmed6, Muinah A. Fowora, Olugbenga O. Aina, Oliver C. Ezechi, Richard A. Adegbola, Babatunde L. Salako, and NIMR COVID-19 response team Covid-19 preparedness and response: experiences of the Nigerian Institute for Medical Research. *The Proceedings of the Nigerian Academy of Science* 2020; 13(1): 4-12
91. Daodu O.B., Shaibu J.O., Richards A.B., Folaranmi E. B., Adegoke S., Ajadi A., Olorunshola D., Akanbi O. B., Afolabi A. A., Daodu O. C., Aiyyedun J. O., Oludairo O. O., Halleed N. I., **Audu R. A.**, Oluwayelu D. O. Detection and molecular characterization of a first isolate of rabbit haemorrhagic disease virus in Nigeria. *Trop Anim Health Prod* 53, 185 (2021). <https://doi.org/10.1007/s11250-021-02606-5>
92. Chukwu EE, Musa AZ, Enwuru C, Ohihion A, Bamidele T, Olukosi A, Idigbe I, Osuolale KA, Gab-Okafor C, Salako A, David O, Otuonye N, David A, Toyosi R, Aina O, Adewale B, Odunukwe NN, Ezechi O, **Audu RA**, Salako BL. Determinants of Antimicrobial Use for Covid-19 Related Symptoms among Nigerians. *West Afr J Med*. 2021 Mar 22;38(3):213-221. PMID: 33764727.
93. Shaibu JO, Salu OB, Amoo OS, Idigbe I, Musa AZ, Ezechi OC, Abejegah C,

- Ayodeji O, Salako BL, Omilabu SA, **Audu RA**. Immunological screening of Lassa Virus among Health workers and Contacts of patients of Lassa fever in Ondo State. *Immunobiology*. 2021 May 1;226(3):152076.
94. Chukwu EE, Oshun PO, Osuolale KA, Chuka-Ebene VO, Salako A, Idigbe IE, Oladele D, **Audu RA**, Ogunsola FT. ANTIMICROBIAL STEWARDSHIP PROGRAMMES IN HEALTHCARE FACILITIES IN LAGOS STATE: A NEEDS ASSESSMENT. *Journal of Global Antimicrobial Resistance*. 2021 Apr 1.
95. Salako AO, Amoo OS, Odubela OO, Osuolale KA, James AB, Oladele DA, Musa AZ, Ige FA, Okwuraiwe AP, Onwuamah CK, Shaibu JO, David AN, **Audu RA**, Ezechi OC, Odunukwe NN and Salako BL. Prevalence and Clinical Characteristics of Coronavirus Disease 2019 Seen at a Testing Centre in Lagos Nigeria. *West African Journal of Medicine*. 2021 Jan 1;38(1):892-6.
96. Steinhardt LC, Ige F, Iriemenam NC, Greby SM, Hamada Y, Uwandu M, Aniedobe M, Stafford KA, Abimiku AL, Mba N, Agala N....., **Audu RA** Cross-reactivity of two SARS-CoV-2 serological assays in a malaria-endemic setting. *Journal of Clinical Microbiology*. 2021 Apr 14: JCM-00514.
97. Ige FA, Ohihoin AG, Amuda BO, Amoo OS, Onwuamah CK, Okwuraiwe AP, Shaibu JO, Odewale EO, James AB, Adeleke K, Adeshina A and **Audu RA**. The Effectiveness of Infection Control Practices Among Health Care Workers Responding to the COVID-19 Pandemic in Nigeria. *Advances in Infectious Diseases*. *Advances in Infectious Diseases* Vol.11 No.2, June 29, 2021  
DOI: 10.4236/aid.2021.112021
98. Christian A. Enwuru, Oluwatoyin O. Awoderu, EmeldaE, Chukwu, EbelechukwuE. Afocha, Lawal G Raman, Peter L. Gogwan, UcheT. Igbasi, **Rosemary A. Audu**. Evaluation of Antibacterial Efficacy of Randomly Selected Alcohol Based Hand Sanitizers Sourced from Grocery Shops within Lagos Metropolis on Some Local Bacterial Strains in COVID-19 Era. *Microbiol Infect Dis*, 2021, Volume 5 (3) 1-9.
99. Okwuraiwe AP, Onwuamah CK, Shaibu JO, Amoo SO, Ige FA, James AB, Okoli LK, Ahmed A, Ponmak J, Sokei JO, Akanmu S, Salako BL, **Audu RA**. (2021) Low level SARS-CoV-2 RNA detected in plasma samples from a cohort of Nigerians: Implications for blood transfusion. *PLoS ONE* 16(6): e0252611.
100. Onwuamah CK, Okwuraiwe AP, Salu OB, Shaibu JO, Ndodo N, Amoo SO, Okoli LC, Ige FA, Ahmed RA, Bankole MA, Sokei JO.... **Audu RA**. Comparative performance of SARS-CoV-2 real-time PCR diagnostic assays on samples from Lagos, Nigeria. *Plos one*. 2021 Feb 4;16(2):e0246637.
101. Olufemi Samuel Amoo, Joseph Shaibu, Olumuyiwa Salu, Ifeoma Idigbe, Zaidat Musa, Gboyega Famokun, Oliver Ezechi, Babatunde Salako, Sunday Omilabu, and **Rosemary Audu**. Comparative Assessment of Knowledge, Attitude/Practices and Prevention of Lassa fever among Community Dwellers and Contacts of Confirmed Patients in Endemic Areas of Ondo State, Nigeria. *European Journal of Medical and Health Sciences ISSN (Online)*: 2593-8339; 2021.

## b. Technical reports and monographs

1. Idigbe EO, Audu RA and Ahonsi B (2003): Profile of The Human Virology Laboratory at The Nigerian Institute of Medical Research, Yaba. Technical Report Commissioned For The Ford Foundation, Lagos, Nigeria.
2. Idigbe EO, Harry TO, Ekong EE, Audu RA, Musa AZ and Funsho-Adebayo EO. (2003). Nigeria's Contributions to Regional and Global Meetings on HIV/AIDS/STIs 1986 – 2003.
3. Idigbe EO, Kanki P, Harry TO, Sankale JL, Akanmu AS, Agwale S, Odutolu O, Onoja AJ, Okafor G, Njoku OS, Onwujekwe D, Uzono LG, Idris Saliu and Audu RA. (2003): Background Document for the Training Modules on Laboratory Tests for Diagnosis and Monitoring of HIV Infection. First Edition, ISBN 978-062-327-2.
4. Idigbe EO, Kanki P, Harry TO, Sankale JL, Akanmu AS, Agwale S, Odutolu O, Onoja AJ, Okafor G, Njoku OS, Onwujekwe D, Uzono LG, Idris Saliu and Audu RA. (2003): Training Manual on Laboratory Tests for the Diagnosis and Monitoring of HIV Infection. First Edition, ISBN 978-062-326-4.
5. Idoko J, Idigbe EO, Ogala WN, Gashau W, Farley J, Akanmu AS, Agbaji OO, Oguche S, Pam S, Matemilola P, Korifama OO, Audu RA, et al (2004): Guidelines for the Use of Antiretroviral (ARV) Drugs in Nigeria. Federal Ministry of Health. ISBN 978-166-463-3.
6. Idigbe EO, Odutolu O, Okonkwo P, Uwakwe C, Jolayemi O, Audu RA and Osagbemi M (2005): Evaluation of The ARV Training Programs Among Health Personnel in Nigeria. ISBN 978-38457-7-2.
7. Idigbe EO, Idika N, Audu RA, Otunonye NM and Onwuamah CK. (2005): Directory of Stakeholders on HIV/AIDS in Nigeria. First Edition, ISBN 978-38457-6-4.
8. Idigbe EO, Harry TO, Ekong EE, Audu RA, Musa AZ, Funsho-Adebayo EO and Onwuamah CK. (2005).Nigeria's Contributions to Regional and Global Meetings on HIV/AIDS/STIs 1986 – 2005, Second Edition, ISBN 978-38457-2-1.
9. Idoko JA, Onwujekwe DI, Agbaji OO, Sonibare SA, Uzono LG, Ezechi OC, Davies A, Ogundiran A, Odunukwe NN, Audu RA et.al. (2005). Training Manuals for Doctors on The Use of Antiretroviral Drugs in Nigeria. First Edition, ISBN 978-38457-3-X.
10. Idigbe EO, Ezechi O, Audu RA and Musa A (2005). Human Capacity Development for Treatment, Care and Support of PLWHA's in Nigeria: 2004 – 2005.ISBN 978-38457-8-0.
11. Osinusi K., Ogala WN, Iroha E, Rabasa AI, Nte A, Adejuyigbe EA, Oguche S, Pam SD, Umar LW, Elon I, Ernest K, Oniyangi O, Mukhtar-Yola, M, Owolabi OA, Ojukwu JU, Eke G, Emokpae A, Audu RA et.al. (2007). National Guidelines for Paeditritic HIV and AIDS Treatment and Care. ISBN 978-978-48611-0-6.
12. Osinusi K., Ogala WN, Iroha E, Rabasa AI, Nte A, Adejuyigbe EA, Oguche S, Pam SD, Umar LW, Elon I, Ernest K, Oniyangi O, Mukhtar-Yola, M, Owolabi OA, Ojukwu JU, Eke G, Emokpae A, Audu RA et.al. (2007). Standard Operating Procedures on Antiretroviral Therapy for Paediatric Patients. ISBN 978-978-48611-1-3.
13. Idoko J, Osinusi K, Adewale I, Gashau W, Akanmu AS, Odunukwe N, Ofondu E, Agbaji OO, Babashani M, Chukwuka C, Ezechi O, Onyedum C, Nwobi E, Onwujekwe D, Audu RA and Oguche S. (2010): National Guidelines for HIV/AIDS Treatment and Care in Adolescednt and Adults. Federal Ministry of Health. ISBN 978-978-085-786-8.

14. Osinusi K., Gashau W, Iroha E, Ogala WN, Oguche S, Umar LW, Elon I, Mukhtar-Yola M, Emodi I, Ene A, Rabasa AI, Adejuyigbe EA, Pam SD, Ernest K, Oniyangi O, Akanmu AS, Audu RA et.al. (2010). National Guidelines for Paediatric HIV and AIDS Treatment and Care. Federal Ministry of Health. ISBN 978-978-48611-0-6.
15. Ojo O, Uzochukwu BSC, Ndububa D, Malu AO, Otegbayo J, Lesi F, Uhunmwaghoh, Uchenna I, Borodo M, Chinemerem OD, Owhonda G, Oguntoye M, Abdusalam I, Okafor C, Musa A, Oyenuga O, Dalhatu N, Dawud AD, Elemeuwa C, Odiabara K, Itodo AO and Audu R et.al. (2016). Guidelines for the Prevention, Treatment and Care of Viral Hepatitis in Nigeria. National AIDS/STIs Control Programme, Federal Ministry of Health. ISBN 978-978-950-907-2.

**c. Gene Submission**

1. Onwuamah CK, Okpokwu J., Chebu P., Audu R.A., Imade G., Samuels J., Odaibo G., Olaleye D., Okonkwo P., Kanki P.J., Idigbe E.O. HIV Drug Resistance: Implications for optimizing antiretroviral therapy (U2G GH000770): Group B Sequences (N=57). Submission: Bankit1960888 (Accession Numbers: MF684375 – MF684431); Submitted 17-AUG-2017.
2. Onwuamah CK, Okpokwu J., Audu R.A., Imade G., Idigbe E.O. HIV Drug Resistance: Implications for optimizing antiretroviral therapy (U2G GH000770): Assay Validation Sequences (N=174). Submission: Bankit2041150 (Accession Numbers: MF684461 – MF684634); Submitted 17-AUG-2017.
3. Onwuamah CK, Olaleye D., Audu R.A., Samuels J., Imade G., Odaibo G., Okpokwu J., Muazu M. and Idigbe E.O. HIV Drug Resistance: Implications for optimizing antiretroviral Therapy: Group A S1 Sequences (N=316). Submission: Bankit2042401 (Accession Numbers: MF754920 – MF755235); Submitted 23-AUG-2017.
4. Salako,B.L., Audu,R.A., Sunday,O.A., Okwuraiwe,A., Amao,O., Shaibu,J.O., Onwuamah,C., James,A., Ajibaye,O., Iwalokun,B., Salu,O., Orenolu,R., Anyanwu,R., Obaleyeye,O., Ige,F., Faleye,T., Abiodun,M., Oni,G. and Olohungbebe,M.: Partial Genomic Sequence and Phylogenetic Analysis of SARS-COV-2 Isolated from an Index Case of Coronavirus Disease 2020 in Nigeria2. (Accession Number: MT159778).

## **IX. MAJOR CONFERENCES ATTENDED (IN THE LAST 5 YEARS)**

### **a. National conferences attended**

1. 7<sup>th</sup> Annual NIMR Scientific Conference, on Health Research in Nigeria: NIMR, 8<sup>th</sup> - 10<sup>th</sup> November, 2016 (**Conference Chair, Presented a talk on Abstract Writing at the Young and Early Scientist Club**)
2. Maiden Conference of SLMTAns in Nigeria, Abuja. November 21<sup>st</sup> – 22<sup>nd</sup>, 2016
3. 2017 Conference of SLMTAns in Nigeria, Abuja. 20<sup>th</sup> -21<sup>st</sup> November 2017. (**Presented a paper on Accredited SLMTA Laboratories - The journey so far [NIMR]**)
4. Nigeria Center for Disease Control Lassa Fever Conference: 16<sup>th</sup> - 17<sup>th</sup> January, 2019

### **b. International conferences attended**

1. 3<sup>rd</sup> African Society for Laboratory Medicine (ASLM) Conference, South Africa. 27 November - 5 December, 2016. (**Presented abstracts: (1) A 10-year trend of HIV types among HIV-positive patients in a reference laboratory; (2) Comparison of Sequencing Success Rates of Viroseq and ATCC HIV-1Drug Resistance Test Kits**)
2. 4<sup>th</sup> NIMR International Scientific Conference, Lagos. 7-9 November, 2017. (**Pre-conference speaker on: Research Ethics in Health Sciences; Developing and Organizing Your Ideas and Research; How To Write a Scientific Paper – A General Guide**)
3. 19<sup>th</sup> International Conference on AIDS and STI's in Africa (ICASA) Abidjan, Cote d'Ivoire - 4 - 9 December 2017.
4. 5<sup>th</sup> NIMR International Scientific Conference, Lagos. 12<sup>th</sup> – 16<sup>th</sup> November, 2018. (**Presented Distinguished Lecturer Titled – “Viruses: Friends or Foes? The Journey to Subdue”**)
5. 4<sup>th</sup> African Society for Laboratory Medicine (ASLM) Conference, Abuja. 10<sup>th</sup> – 13<sup>th</sup> December, 2018.
6. 6<sup>th</sup> NIMR International Scientific Conference, Lagos. 12<sup>th</sup> – 14<sup>th</sup> November 2019.
7. 7<sup>th</sup> NIMR International Scientific Conference, Lagos. 17<sup>th</sup> – 18<sup>th</sup> November 2020.